Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction

Pharmacogenetics

Volumn 6, Issue 5, 1996, Pages 417-421

  Stüven, Thomas ^a   Griese, Ernst Ulrich ^a   Kroemer, Heyo K ^a   Eichelbaum, Michel ^a   Zanger, Ulrich M ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

CYP2D6; Cytochrome P450; Genetic polymorphism; Genotyping; Multiplex PCR

Indexed keywords

CYTOCHROME P450; DNA; SPARTEINE;

AEROBIC METABOLISM; ALLELE; ARTICLE; CAUCASIAN; CHROMOSOME 22; CONTROLLED STUDY; DRUG METABOLISM; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MUTATION; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TECHNIQUE;

ALLELES; CHROMOSOMES, HUMAN, PAIR 22; CYTOCHROME P-450 CYP2D6; DNA PRIMERS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; GERMANY; HUMANS; MUTATION; PHARMACEUTICAL PREPARATIONS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC;

EID: 0029846193     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-199610000-00005     Document Type: Article

References (20)

1. Bock KW, Schrenk D, Forster A, Griese EU, Mörike K, Brockmeier D, Eichelbaum M. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyl-transferases in man using sparteine, caffeine, and paracetamol as probes. Pharmacogenetics 1994: 4, 209-218.
2. Broly F, Marez D, Sabbagh N, Legrand M, Boone P, Meyer UA. An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 1995: 5, 373-384.
3. Cheng S, Fockler C, Barnes WM, Higuchi R. Effective amplification of long targets from cloned inserts and human genomic DNA. Proc Natl Acad Sci USA 1994: 91, 5695-5699.
4. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang J-D, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR, Zanger UM. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996: 6, 193-201.
5. Douglas AM, Atchison BA, Somogyi AA, Drummer OH. Interpretation of a simple PCR analysis of the CYP2D6(A) and CYP2D6(B) null alleles associated with the debrisoquine/ sparteine genetic polymorphism. Pharmacogenetics 1994: 4, 154-158.
6. Evert B, Griese E-U, Eichelbaum M. Cloning and sequencing of a new non-functional CYT2D6 allele: Deletion of T1795 in exon 3 generates a premature stop codon. Pharmacogenetics 1994A: 4, 271-274.
7. Evert B, Griese E-U, Eichelbaum M. A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine. Naunyn-Schmiedeberg's Arch Pharmacol 1994B: 350, 434-439.
8. Gaedigk A, Blum M, Gaedigk R, Eichelbaum M, Meyer UA. Deletion of the entire cytochrome P4502D6 gene as a cause of impaired drug metabolism in poor metabolizers of the debrisoquine/ sparteine polymorphism. Am J Hum Genet 1991: 48, 943-950.
9. Heim MH, Meyer UA. Genotyping of poor metabolizers of debrisoquine by allele specific PCR amplification. Lancet 1990: 336, 529-532.
10. Johansson I, Lundqvist E, Bertilsson L, Dahl M-L, Sjöqvist F, Ingelman-Sundberg M. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993: 90, 11825-11829.
11. Kagimoto M, Heim M, Kagimoto K, Zeugin T, Meyer UA. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine: a study of the functional significance of individual mutations by expression of chimeric genes. J Biol Chem 1990: 265, 17209-17216.
12. Kimura S, Umeno M, Skoda RC, Meyer UA, Gonzalez FJ. The human debrisoquine 4-hydroxylase (CYP2D) locus: Sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. Am J Hum Genet 1989: 45, 889-904.
13. Kroemer HK, Eichelbaum M. 'It's the genes, stupid': Molecular basis and clinical consequences of genetic cytochrome P4502D6 polymorphism. Life Sci 1995: 56, 2285-2298.
14. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F. A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 1995: 5, 305-311.
15. Saxena R, Shaw GL, Reilling MV, Frame JN, Moir DT, Evans WE, Caporaso N, Weiffenbach B. Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotype. Hum Mol Genet 1994: 3, 923-926.
16. Skoda RC, Gonzalez FJ, Demierre A, Meyer UA. Two mutant alleles of the human cytochrome P450db1 gene associated with genetically deficient metabolism of debrisoquine and other drugs. Proc Natl Acad Sci USA 1988: 85, 5240-5243.
17. Steen VM, Andreassen OA, Daly AK, Tefre T, Borresen A-L. Idle JR, Gulbrandsen A-K. Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics 1995: 5, 215-223.
18. Tefre T, Daly AK, Armstrong M, Leathart JBS, Idle JR, Brogger A, Borresen A-L. Genotyping of the CYP2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics 1994: 4, 47-57.
19. Wang S-L, Huang J-D, Lai M-D, Liu B-H, Lai M-L. Molecular basis of genetic variation in debrisoquine hydroxylation in Chinese subjects: Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 1993: 53, 410-418.
20. Yokota H, Tamura S, Furuya H, Kimura S, Watanabe M, Kanazawa I, Kondo I, Gonzalez FJ. Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism. Pharmacogenetics 1993: 3, 256-263.